News
DNA
0.7777
-8.05%
-0.0681
Tuesday's ETF Movers: ARKG, PICK
NASDAQ · 2d ago
Weekly Report: what happened at DNA last week (0415-0419)?
Weekly Report · 3d ago
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Seeking Alpha · 6d ago
GINKGO BIOWORKS HOLDINGS INC <DNA.N>: BOFA GLOBAL RESEARCH CUTS PRICE OBJECTIVE TO $1 FROM $1.25
Reuters · 04/17 13:42
Ginkgo Bioworks and Il Granaio delle Idee enter into a collaboration
Ginkgo Bioworks and Il Granaio delle Idee enter into a collaboration. IGDI has identified a new sourdough bakery strain that can improve the flavor and aroma profile of baked goods. The company will leverage Ginkgo's technology to improve its starter culture product.
Seeking Alpha · 04/16 11:24
Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products
IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product, Pater. IGDI has identified a new strain that can improve the flavor and aroma of baked goods. Pater is a dried baking mix that keeps lactic acid bacteria dispersed in flour stable over time.
PR Newswire · 04/16 11:02
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.
Novo Nordisk and Ginkgo Bioworks have launched a new manufacturing collaboration. The focus will be on manufacturing therapies for chronic diseases. The collaboration could help solve challenges for both businesses. But investors should be wary of the risks of investing in either company now. Novo's blockbuster diabetes drug Ozempic is in a state of shortage.
The Motley Fool · 04/15 14:00
Weekly Report: what happened at DNA last week (0408-0412)?
Weekly Report · 04/15 09:11
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Zoetis (ZTS) and Ginkgo Bioworks Holdings (DNA)
TipRanks · 04/15 01:40
Modalis Therapeutics Partners With Ginkgo Bioworks, Enhancing Cell And Gene Therapy With CRISPR-GNDM® Technology
Modalis Therapeutics Corporation to join the Ginkgo Technology Network. The company's CRISPR-GNDM technology is capable of activating or suppressing any gene without DNA cleavage. Customers in the cell and gene therapy fields will be able to access Modalis' technology.
Benzinga · 04/12 07:10
What's Going On With Ginkgo Bioworks Stock?
Ginkgo Bioworks Holdings, Inc. Announced the acquisition of AgBiome’s platform assets. The company also announced the expansion of its strategic partnership with Novo Nordisk A/S. DNA shares are volatile after the company announced its acquisition of the company's assets.
Benzinga · 04/11 19:07
Ginkgo Bioworks acquires AgBiome's platform assets
Cell platform company Ginkgo Bioworks acquires AgBiome's platform assets. Financial terms of the transaction were not disclosed. The company bought Bayer's agricultural biologicals R&D facility in 2022. Gink go bioworks will buy Ag biome's biological assets.
Seeking Alpha · 04/11 11:45
Ginkgo Bioworks Reports Acquisition Of AgBiome's Platform Assets
The deal includes over 115,000 fully sequenced strains and 500 million unique gene sequences. AgBiome's development pipeline will be integrated into Ginkgo Ag Biologicals Services in 2022. The assets will include over 500 million gene sequences and functional data and metadata.
Benzinga · 04/11 11:19
Ginkgo Bioworks Acquires Microbial Innovation Firm AgBiome's Platform Assets
NASDAQ · 04/11 11:14
GINKGO BIOWORKS HOLDINGS INC: ASSETS WILL BE INTEGRATED INTO GINKGO AG BIOLOGICALS SERVICES
Reuters · 04/11 11:01
Ginkgo Bioworks Announces Acquisition of AgBiome's Platform Assets
Ginkgo Bioworks is building the leading platform for cell programming and biosecurity. AgBiome's platform assets include over 115,000 strains, over 500 million unique gene sequences, and a robust development pipeline. The assets will be integrated into Ginkgo Ag Biologicals Services.
PR Newswire · 04/11 11:01
Ginkgo Bioworks Previews Today's Annual Ferment Conference, Announces "Lab Data as a Service"
Ginkgo Bioworks is hosting its 5th annual Ferment conference in Boston. The conference brings together stakeholders from across the synthetic biology community. Ginkgo is building the leading platform for cell programming and biosecurity. Ferment will begin with a keynote address from Jason Kelly.
PR Newswire · 04/11 11:01
Press Release: Ginkgo Bioworks Announces Acquisition of AgBiome's Platform Assets
Ginkgo Bioworks Announces Acquisition of AgBiome's Platform Assets. Ginkgo is building the leading platform for cell programming and biosecurity. The assets include over 115,000 fully sequenced strains, over 500 million unique gene sequences, and a robust development pipeline. These assets will be integrated into Gink go's Ag Biologicals Services.
Dow Jones · 04/11 11:01
Ginkgo Bioworks expands R&D tie-up with Novo Nordisk
Ginkgo Bioworks expands R&D tie-up with Novo Nordisk to improve production of key drugs. Bill & Melinda Gates Foundation awards Ginkgo a grant to develop an AI-driven measles forecasting model. The companies will collaborate on technology exploration across Novo's drug portfolio.
Seeking Alpha · 04/10 11:34
Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&amp;D Value Chain
Ginkgo Bioworks announced the expansion of its strategic partnership with global healthcare leader Novo Nordisk. The partners aim to improve the manufacturing of Novo's medicines for serious chronic diseases. The companies plan to collaborate on several early pipeline projects. Ginkgo is developing the leading platform for cell programming and biosecurity.
PR Newswire · 04/10 11:02
More
Webull provides a variety of real-time DNA stock news. You can receive the latest news about Ginkgo Bioworks Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About DNA
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.